第61回日本神経学会学術大会

セッション情報

印刷

シンポジウム

[S-39] シンポジウム39
The concept of MOG-IgG positive diseases

2020年9月1日(火) 16:00 〜 17:30 第06会場 (岡山コンベンションセンター 2F レセプションホール)

座長：中島 一郎（東北医科薬科大学医学部老年神経内科学）,三須 建郎（東北大学大学院医学系研究科神経内科）

[S-39-1] MOG-IgG assays and their clinical associations in children

○Patrick Waters (University of Oxford)

Auto-antibodies (IgG) against myelin oligodendrocyte glycoprotein (MOG) are detected in the serum of patients with various demyelinating diseases. These patients are known to show repeated clinical episodes of inflammatory demyelinating attacks in the central nervous system. Although the associated pathogenicity and mechanism of inflammatory demyelination remains inconclusive, it is known that patients with MOG-IgG have a different clinical spectrum from those with other demyelinating diseases, such as multiple sclerosis. We conducted this symposium to understand the clinical features and the spectrum of MOG-IgG related demyelinating diseases.

[S-39-2] Clinical manifestation of MOG-IgG associated encephalomyelitis

○Sung Min Kim (Seoul National University Hospital)

Auto-antibodies (IgG) against myelin oligodendrocyte glycoprotein (MOG) are detected in the serum of patients with various demyelinating diseases. These patients are known to show repeated clinical episodes of inflammatory demyelinating attacks in the central nervous system. Although the associated pathogenicity and mechanism of inflammatory demyelination remains inconclusive, it is known that patients with MOG-IgG have a different clinical spectrum from those with other demyelinating diseases, such as multiple sclerosis. We conducted this symposium to understand the clinical features and the spectrum of MOG-IgG related demyelinating diseases.

[S-39-3] 抗MOG抗体陽性疾患の免疫病態

○金子 仁彦1,2 (1.国立病院機構宮城病院 脳神経内科, 2.東北大学 脳神経内科)

Auto-antibodies (IgG) against myelin oligodendrocyte glycoprotein (MOG) are detected in the serum of patients with various demyelinating diseases. These patients are known to show repeated clinical episodes of inflammatory demyelinating attacks in the central nervous system. Although the associated pathogenicity and mechanism of inflammatory demyelination remains inconclusive, it is known that patients with MOG-IgG have a different clinical spectrum from those with other demyelinating diseases, such as multiple sclerosis. We conducted this symposium to understand the clinical features and the spectrum of MOG-IgG related demyelinating diseases.

[S-39-4] Pathology of MOG-IgG diseases

○髙井 良樹1, 三須 建郎1, 藤原 一男1,2, 青木 正志1 (1.東北大学病院 脳神経内科, 2.福島医科大学 多発性硬化症治療学寄付講座)

Auto-antibodies (IgG) against myelin oligodendrocyte glycoprotein (MOG) are detected in the serum of patients with various demyelinating diseases. These patients are known to show repeated clinical episodes of inflammatory demyelinating attacks in the central nervous system. Although the associated pathogenicity and mechanism of inflammatory demyelination remains inconclusive, it is known that patients with MOG-IgG have a different clinical spectrum from those with other demyelinating diseases, such as multiple sclerosis. We conducted this symposium to understand the clinical features and the spectrum of MOG-IgG related demyelinating diseases.

[S-39-5] 抗MOG抗体関連疾患の小児例

○池田 尚広, 山形 崇倫 (自治医科大学小児科)

Auto-antibodies (IgG) against myelin oligodendrocyte glycoprotein (MOG) are detected in the serum of patients with various demyelinating diseases. These patients are known to show repeated clinical episodes of inflammatory demyelinating attacks in the central nervous system. Although the associated pathogenicity and mechanism of inflammatory demyelination remains inconclusive, it is known that patients with MOG-IgG have a different clinical spectrum from those with other demyelinating diseases, such as multiple sclerosis. We conducted this symposium to understand the clinical features and the spectrum of MOG-IgG related demyelinating diseases.